{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["13(18)"],"submitter":["Tang Q"],"pubmed_abstract":["<h4>Background</h4>The poor overall survival of osteosarcoma (OS) underscores the need to explore new therapeutic avenues. Tumor necrosis rate (TNR) after neoadjuvant chemotherapy predicts prognosis.<h4>Aims</h4>The study was to investigate safety and activity of neoadjuvant chemotherapy with camrelizumab (a humanized antibody against PD-1) in patients with resectable OS.<h4>Materials & methods</h4>We conducted a prospective, single-arm, exploratory phase II trial in OS patients. Eligible patients received camrelizumab combined with doxorubicin or liposomal doxorubicin, cisplatin, methotrexate, ifosfamide with mesna. Surgery was performed 12-14 days after neoadjuvant therapy and adjuvant therapy starting 2-3 weeks postoperatively. The primary endpoint was the rate of good tumor necrosis (T"],"journal":["Cancer medicine"],"pagination":["e70206"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11424980"],"repository":["biostudies-literature"],"pubmed_title":["Camrelizumab in combination with doxorubicin, cisplatin, ifosfamide, and methotrexate in neoadjuvant treatment of resectable osteosarcoma: A prospective, single-arm, exploratory phase II trial."],"pmcid":["PMC11424980"],"pubmed_authors":["Deng C","Ai F","Tang Q","Zhang Y","Zhang X","Lu J","Zhu X","Xu H","Song G","Wang J","Wu H"],"additional_accession":[]},"is_claimable":false,"name":"Camrelizumab in combination with doxorubicin, cisplatin, ifosfamide, and methotrexate in neoadjuvant treatment of resectable osteosarcoma: A prospective, single-arm, exploratory phase II trial.","description":"<h4>Background</h4>The poor overall survival of osteosarcoma (OS) underscores the need to explore new therapeutic avenues. Tumor necrosis rate (TNR) after neoadjuvant chemotherapy predicts prognosis.<h4>Aims</h4>The study was to investigate safety and activity of neoadjuvant chemotherapy with camrelizumab (a humanized antibody against PD-1) in patients with resectable OS.<h4>Materials & methods</h4>We conducted a prospective, single-arm, exploratory phase II trial in OS patients. Eligible patients received camrelizumab combined with doxorubicin or liposomal doxorubicin, cisplatin, methotrexate, ifosfamide with mesna. Surgery was performed 12-14 days after neoadjuvant therapy and adjuvant therapy starting 2-3 weeks postoperatively. The primary endpoint was the rate of good tumor necrosis (T","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Sep","modification":"2025-04-05T08:57:46.901Z","creation":"2025-04-05T08:57:46.901Z"},"accession":"S-EPMC11424980","cross_references":{"pubmed":["39324173"],"doi":["10.1002/cam4.70206"]}}